Description

TENORMIN 50MG (1X14)

Indications

TENORMIN, containing the active ingredient atenolol, is primarily indicated for the management of hypertension (high blood pressure) and for the prevention of angina pectoris (chest pain). It is also utilized in the treatment of myocardial infarction (heart attack) and may be prescribed for patients with certain types of arrhythmias. By effectively lowering blood pressure and reducing heart workload, TENORMIN helps in decreasing the risk of cardiovascular events.

Mechanism of Action

Atenolol, the active substance in TENORMIN, is a selective beta-1 adrenergic receptor blocker. It works by inhibiting the effects of catecholamines (such as adrenaline) on the heart. By blocking these receptors, atenolol decreases heart rate, myocardial contractility, and conduction velocity through the atrioventricular node. This results in a reduction in cardiac output and a subsequent decrease in blood pressure. Additionally, atenolol reduces oxygen demand by the heart, making it beneficial in managing angina.

Pharmacological Properties

TENORMIN is characterized by its pharmacokinetic properties, including oral bioavailability of approximately 50%, with peak plasma concentrations achieved within 2 to 4 hours post-administration. The drug has a half-life of about 6 to 7 hours, allowing for once-daily dosing in most cases. Atenolol is primarily eliminated by the kidneys, and its pharmacodynamic effects can last up to 24 hours, making it suitable for once-daily administration.

Contraindications

TENORMIN is contraindicated in patients with known hypersensitivity to atenolol or any of the excipients in the formulation. It should not be used in individuals with severe bradycardia (slow heart rate), heart block greater than first degree (unless a pacemaker is present), cardiogenic shock, or overt heart failure. Additionally, caution is advised in patients with a history of asthma or chronic obstructive pulmonary disease (COPD), as beta-blockers can potentially exacerbate bronchospasm.

Side Effects

Common side effects associated with the use of TENORMIN include fatigue, dizziness, and gastrointestinal disturbances such as nausea and diarrhea. Other potential side effects may include cold extremities, bradycardia, hypotension, and sleep disturbances. Rare but serious side effects can include severe allergic reactions, worsening of heart failure, or signs of liver dysfunction. Patients are advised to report any unusual symptoms to their healthcare provider promptly.

Dosage and Administration

The recommended starting dose of TENORMIN for hypertension is typically 50 mg once daily. Depending on the patient’s response, the dosage may be adjusted, with a maximum recommended dose of 100 mg per day. For angina pectoris, the usual starting dose is also 50 mg once daily, with potential titration based on clinical response. In cases of myocardial infarction, treatment may begin with a loading dose followed by a maintenance dose as prescribed by the healthcare provider. It is essential to take TENORMIN at the same time each day to maintain consistent blood levels of the medication.

Interactions

TENORMIN may interact with other medications, which can alter its effects or increase the risk of side effects. Notable interactions include those with other antihypertensive agents, which may lead to additive effects and excessive hypotension. Nonsteroidal anti-inflammatory drugs (NSAIDs) can reduce the antihypertensive effect of atenolol. Additionally, caution is advised when combining atenolol with other medications that can cause bradycardia, such as digoxin or certain antiarrhythmics. Patients should inform their healthcare provider of all medications they are taking to avoid potential interactions.

Precautions

Before initiating treatment with TENORMIN, a thorough medical history should be obtained. Special precautions should be taken in patients with renal impairment, as atenolol is primarily excreted by the kidneys. Dose adjustments may be necessary in these individuals. Additionally, caution is warranted in patients with diabetes, as beta-blockers can mask the symptoms of hypoglycemia. Abrupt discontinuation of TENORMIN should be avoided, as it may lead to rebound hypertension or exacerbation of angina. A gradual tapering of the dose is recommended when discontinuing the medication.

Clinical Studies

Numerous clinical studies have demonstrated the efficacy of atenolol in managing hypertension and preventing cardiovascular events. In a randomized controlled trial, patients treated with atenolol showed significant reductions in systolic and diastolic blood pressure compared to placebo. Furthermore, studies have indicated that atenolol can effectively reduce the incidence of angina attacks and improve exercise tolerance in patients with stable angina. Long-term follow-up studies have also suggested that atenolol may reduce mortality in patients who have experienced myocardial infarction, supporting its use in secondary prevention.

Conclusion

TENORMIN 50MG is a well-established medication for the management of hypertension, angina, and post-myocardial infarction care. With its selective beta-1 adrenergic receptor blocking action, atenolol effectively lowers blood pressure and reduces heart workload, contributing to improved cardiovascular health. While generally well-tolerated, it is essential for patients to be aware of potential side effects and drug interactions. Regular follow-up with healthcare providers is crucial to ensure optimal therapeutic outcomes and to make necessary adjustments to the treatment regimen.